Positives

• The ACTIV-1 randomized trial found a mortality benefit and improved clinical status in hospitalized COVID-19 adults treated with infliximab NIH.
  
  
• A patient on infliximab plus tocilizumab in cytokine-storm COVID showed measurable benefit over tocilizumab alone Nature.
  
  

Negatives

• Seroconversion and antibody magnitude were significantly reduced versus vedolizumab, raising reinfection risk PMC.
  
  
• A multicenter case series reported severe COVID with hospitalizations of 10-66 days following infusion PMC.
  
  

Hurdles & Side Effects

• Each dose requires an in-clinic IV infusion of several hours every 4-8 weeks PubMed.
  
  
• Patients on infliximab were advised by gastroenterologists they would need extra COVID booster doses for protection Healio.